ArticleFrontiers in immunology2025
Identification of a prognostic signature based on immunogenic adverse event-related genes to guide therapy for non-small cell lung cancer.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitors (ICIs) improve outcomes in non-small cell lung cancer (NSCLC), yet reliable predictive biomarkers are still lacking. Given that immune-related adverse events (irAEs) often correlate with better ICI efficacy, this study aimed to develop and validate an irAE-related gene signature for risk stratification and treatment-response prediction in NSCLC. Methods: Transcriptomic and clinical data were obtained from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases, designated as training and validation cohorts, respectively. Least absolute shrinkage and selection operator (LASSO) regression and Cox proportional hazards models were applied to identify eight irAE-associated genes for constructing a risk score (RS). Multivariate analyses evaluated differences in overall survival (OS), immunotherapy response, irAE incidence, immune escape potential, and tumor microenvironment (TME) profiles between high- and low-risk groups. Prognostic performance was validated using Kaplan-Meier curves, Cox regression, and receiver operating characteristic (ROC) analysis. A nomogram integrating RS with clinical factors was developed to improve prediction stability. Results: Via gene set variation analysis (GSVA) enrichment of 30 known immunologic gene sets in TCGA-LC, we stratified samples by immune score (cutoff = 0.23), identified 1,057 differentially expressed genes (DEGs) between groups, intersected with cancer-normal DEGs, and selected 132 irAE-related DEGs via Pearson correlation-genes functionally tied to T-cell activation and cytokine-mediated signaling pathways. LASSO-Cox regression derived an eight-gene prognostic signature demonstrating robust cross-cohort validation [area under the curve (AUC): TCGA = 0.770, GSE50081 = 0.767, GSE37745 = 0.758] and predictive accuracy for irAEs in GSE186143 (AUC = 0.807). In a validation NSCLC cohort ( Conclusions: Our irAE-associated gene signature robustly stratifies NSCLC patients for immunotherapy response and survival. Integrating RS with clinical parameters provides a practical tool to balance efficacy and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.